Ensovibep - CISMeF

Preferred Label : Ensovibep;

NCIt definition : A designed ankyrin repeat proteins (DARPin)-based, tri-specific agent composed of three severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein (SP) receptor-binding domain (RBD) binding domains that bind to the same epitope region on the SARS-CoV-2 SP RBD and a human serum albumin (HSA)-binding domain, that can potentially be used for immunization against COVID-19. Upon administration, ensovibep specifically targets and binds to three epitopes in the same SARS-CoV-2 SP RBD region, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. Binding to three epitopes of the SARS-CoV-2 SP RBD may decrease the potential for viral escape through mutations. The HSA-binding domain binds to HSA which prolongs the half-life of the agent.;

UNII : PV6AA88RDU;

CAS number : 2451126-06-8;

Molecule name : MP 0420; MP-0420;

NCI Metathesaurus CUI : CL1648533;

Details

Origin ID

C179065;

UMLS CUI

C5544680;

Currated CISMeF NLP mapping
- ensovibep [MeSH concept]
- ensovibep [MeSH Supplementary Concept]
False automatic mappings
- cardiac complexes, premature [MeSH Descriptor]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- ensovibep [MeSH Supplementary Concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients